- Home
- KYMR vs GH Comparison
KYMR vs GH Comparison
Compare KYMR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- GH
- Stock Information
- Founded
- KYMR 2015
- GH 2011
- Country
- KYMR United States
- GH United States
- Employees
- KYMR N/A
- GH N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- GH Medical Specialities
- Sector
- KYMR Health Care
- GH Health Care
- Exchange
- KYMR Nasdaq
- GH Nasdaq
- Market Cap
- KYMR 4.3B
- GH 4.9B
- IPO Year
- KYMR 2020
- GH 2018
- Fundamental
- Price
- KYMR $59.94
- GH $93.58
- Analyst Decision
- KYMR Strong Buy
- GH Strong Buy
- Analyst Count
- KYMR 19
- GH 22
- Target Price
- KYMR $66.84
- GH $74.32
- AVG Volume (30 Days)
- KYMR 631.1K
- GH 2.7M
- Earning Date
- KYMR 11-04-2025
- GH 10-29-2025
- Dividend Yield
- KYMR N/A
- GH N/A
- EPS Growth
- KYMR N/A
- GH N/A
- EPS
- KYMR N/A
- GH N/A
- Revenue
- KYMR $43,735,000.00
- GH $902,569,000.00
- Revenue This Year
- KYMR $60.88
- GH $28.28
- Revenue Next Year
- KYMR N/A
- GH $23.00
- P/E Ratio
- KYMR N/A
- GH N/A
- Revenue Growth
- KYMR N/A
- GH 30.38
- 52 Week Low
- KYMR $19.45
- GH $22.92
- 52 Week High
- KYMR $63.96
- GH $100.08
- Technical
- Relative Strength Index (RSI)
- KYMR 55.80
- GH 73.79
- Support Level
- KYMR $55.66
- GH $68.02
- Resistance Level
- KYMR $63.36
- GH $100.21
- Average True Range (ATR)
- KYMR 3.07
- GH 4.36
- MACD
- KYMR -0.37
- GH 2.84
- Stochastic Oscillator
- KYMR 57.78
- GH 81.68
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.